NIH CRADA reasonable pricing clause removal under "serious discussion," NIH rep tells AIDS task force.
NIH CRADA REASONABLE PRICING CLAUSE COULD BE DROPPED, NIH officials say. Removal of the pricing clause from CRADA contracts is an option that is "under the most serious discussion at this point" among National Institutes of Health and Public Health Service representatives, NIH Acting Deputy Director for Science Policy & Technology Transfer Sandy Chamblee told the National Task Force on AIDS Drug Development in Bethesda, Md. on Jan. 19. Chamblee noted that at the December meetings of both the PHS Technology Transfer Board and NIH Advisory Board to the Director, participants agreed that the reasonable pricing clause in cooperative research and development agreements "should not be permitted to impede scientific collaboration" and "NIH itself is not a regulatory agency and should not take on a price-setting role."
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’